BioCryst Pharmaceuticals | BCRX - Betriebsaufwand





Betriebsaufwand Veränderung Datum
Alnylam Pharmaceuticals USD 1.06B 160.97M 2026-06
BioCryst Pharmaceuticals USD 119.78M 673.63M 2026-06
Chugai Pharma JPY 180.73B 17.74B 2026-06
Daiichi Sankyo JPY 489.64B 21.08B 2026-06
DBV Technologies USD 47.9M 2.2M 2026-03
Enanta Pharmaceuticals USD 126.59M 346.51M 2025-12
Gilead Sciences USD 3.95B 19.57B 2026-06
GlaxoSmithKline GBP 5.8B 468M 2026-06
Glaxosmithkline GBP 5.34B 3.83B 2026-03
Incyte USD 973.64M 4.65B 2026-06
Ionis Pharmaceuticals USD 370.24M 6.24M 2026-06
Karyopharm Therapeutics USD 61.83M 9.9M 2026-03
Neurocrine Biosciences USD 739.1M 139.2M 2026-06
Novavax USD 126.2M 23.62M 2025-12
PTC Therapeutics USD 226.66M 19.64M 2026-03
Regeneron Pharmaceuticals USD 31.71B 287.8M 2026-06
Roche Holding CHF 18.9B 2.12B 2026-06
Sarepta Therapeutics USD 387.96M 15.59M 2026-06
Ultragenyx Pharmaceutical USD 289M 16M 2026-06
Vertex Pharmaceuticals USD 2.07B 217.1M 2026-06